Shingles vaccine: among the most effective adult shots, and who it is for

The recombinant shingles vaccine is among the most effective vaccines available to adults: in its pivotal trials it prevented roughly 90 to 97 percent of shingles cases, depending on age [s1][s2]. US guidelines recommend two doses for all adults from age 50, and for immunocompromised adults from age 19, given two to six months apart [s3]. It replaced an older live vaccine that was substantially less effective, particularly in the oldest recipients [s2].

Shingles is a reactivation of the varicella-zoster virus that causes chickenpox; the virus stays dormant in nerve tissue for decades and can re-emerge as a painful rash, most commonly in older adults and people with weakened immune systems [s3]. Its most feared complication is post-herpetic neuralgia, nerve pain that can persist for months after the rash clears [s2].

What the trials showed

Two large randomised, placebo-controlled trials established the efficacy. ZOE-50 enrolled adults aged 50 and older across 18 countries and found overall vaccine efficacy against shingles of 97.2% (95% confidence interval 93.7 to 99.0), with efficacy between 96.6% and 97.9% across every age band studied — including, notably, no drop-off in the oldest participants [s1]. ZOE-70, run concurrently in adults 70 and older, found efficacy of 89.8% (95% CI 84.2 to 93.7), similar in those aged 70–79 and those 80 and over [s2]. In participants 70 and older pooled from both trials, efficacy against shingles was 91.3% and against post-herpetic neuralgia 88.8% (95% CI 68.7 to 97.1) [s2].

That the vaccine held up in the oldest recipients is its central advantage. Many vaccines weaken with age as the immune system responds less vigorously; the recombinant shingles vaccine pairs a viral protein with an adjuvant designed to boost that response, and the trials showed it largely overcame the usual age-related decline [s1][s2].

The trade-off: reactogenicity

Effectiveness came with a noticeable rate of short-term reactions. In ZOE-50, grade 3 symptoms — severe enough to prevent normal activities — were reported by 17.0% of vaccine recipients versus 3.2% of placebo recipients [s1]. In ZOE-70, injection-site and systemic reactions within seven days were far more common after the vaccine than placebo (79.0% versus 29.5%) [s2]. These reactions, typically sore arm, fatigue, muscle pain and headache, usually resolved within a few days, but they are frequent enough that recipients are often advised to expect them, especially after the second dose [s2].

Eligibility and what remains uncertain

The CDC recommends the two-dose series for immunocompetent adults 50 and older and for adults 19 and older who are or will be immunosuppressed, a group at higher shingles risk in whom the vaccine was subsequently studied [s3]. The trials measured efficacy over their follow-up periods; how well protection persists over the very long term, and the exact value of any future booster, are questions the original trials could not answer and that longer-term follow-up continues to address [s1][s2].

Beyond preventing shingles, observational research has explored whether the vaccine associates with lower cardiovascular risk — a separate and less certain question than its established efficacy against the rash and its nerve-pain complication. On the core outcome the evidence is unusually strong: this is a highly effective vaccine with a real but generally short-lived reactogenicity cost [s1][s2][s3]. This is informational reporting on guideline recommendations, not medical advice; vaccination decisions belong with a clinician.